Top Nanotechnology Stocks Worth Watching – March 21st

OSI Systems, Virpax Pharmaceuticals, NVE, Biodexa Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares in companies involved in the research, development, or production of products that utilize nanoscale materials and processes. These companies often apply breakthroughs in nanotechnology across various sectors—such as healthcare, electronics, and energy—to develop innovative solutions that capitalize on the unique properties of materials at the molecular level. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ:OSIS traded down $3.44 during trading on Friday, reaching $194.00. 97,790 shares of the stock were exchanged, compared to its average volume of 169,064. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25. The stock has a fifty day moving average of $192.04 and a two-hundred day moving average of $168.52. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of 24.97, a price-to-earnings-growth ratio of 1.81 and a beta of 1.20. OSI Systems has a 1-year low of $126.57 and a 1-year high of $220.00.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

NASDAQ VRPX traded down $0.27 on Friday, reaching $2.23. The company had a trading volume of 1,890,947 shares, compared to its average volume of 344,056. The company’s fifty day moving average is $0.26 and its 200 day moving average is $0.46. Virpax Pharmaceuticals has a 52-week low of $2.09 and a 52-week high of $107.50.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NASDAQ NVEC traded down $0.50 during mid-day trading on Friday, reaching $64.90. 17,215 shares of the company’s stock were exchanged, compared to its average volume of 23,957. The firm has a market capitalization of $313.90 million, a price-to-earnings ratio of 20.93 and a beta of 1.08. NVE has a 52 week low of $63.65 and a 52 week high of $90.24. The firm has a 50-day moving average price of $71.67 and a two-hundred day moving average price of $76.26.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of NASDAQ:BDRX traded down $0.16 during mid-day trading on Friday, reaching $1.84. The company had a trading volume of 224,107 shares, compared to its average volume of 509,274. The company has a 50-day simple moving average of $3.73. Biodexa Pharmaceuticals has a one year low of $1.83 and a one year high of $74.00.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ:CLNN traded down $0.02 on Friday, reaching $4.25. 16,529 shares of the company’s stock were exchanged, compared to its average volume of 50,856. Clene has a 52 week low of $3.82 and a 52 week high of $9.20. The firm has a market cap of $35.39 million, a price-to-earnings ratio of -0.80 and a beta of 0.27. The stock has a fifty day simple moving average of $4.59 and a 200-day simple moving average of $4.95.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of NASDAQ CLNNW remained flat at $0.03 during mid-day trading on Friday. The stock had a trading volume of 30 shares, compared to its average volume of 14,501. The business’s 50-day simple moving average is $0.04 and its 200-day simple moving average is $0.04. Clene has a one year low of $0.02 and a one year high of $0.08.